University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven

Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer (2021) Muilwijk T, Akand M, Van Der Aa F, De Coninck V, Claessens M, Hente R, Eckstein M, et al. Journal article High-grade Transformation/Dedifferentiation in Salivary Gland Carcinomas: Occurrence Across Subtypes and Clinical Significance (2021) Skalova A, Leivo I, Hellquist H, Agaimy A, Simpson RH, Stenman G, Vander Poorten V, et al. Journal article Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium (2021) Morra A, Jung AY, Behrens S, Keeman R, Ahearn TU, Anton-Culver H, Arndt V, et al. Journal article An International Multicenter Real-Life Prospective Study of Electronic Chromoendoscopy Score PICaSSO in Ulcerative Colitis (2021) Iacucci M, Smith SC, Bazarova A, Shivaji UN, Bhandari P, Cannatelli R, Daperno M, et al. Journal article Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk (2021) Kapoor PM, Mavaddat N, Choudhury PP, Wilcox AN, Lindström S, Behrens S, Michailidou K, et al. Journal article Idecabtagene vicleucel in relapsed and refractory multiple myeloma (2021) Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, et al. Journal article Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/ trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial (2021) Hurvitz SA, Fresco R, Afenjar K, Stroyakovskiy D, Huang CS, Wildiers H, Jung KH, et al. Conference contribution Nocturnal respiratory rate predicts ICD benefit: A prospective, controlled, multicentre cohort study (2021) Dommasch M, Steger A, Barthel P, Huster KM, Mueller A, Sinnecker D, Laugwitz KL, et al. Journal article Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study (2021) Goessens L, Colombel JF, Outtier A, Ferrante M, Sabino J, Judge C, Saeidi R, et al. Journal article Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials (2021) Fasching P, Harbeck N, Jerusalem G, Colleoni MA, Neven P, Franke F, De Laurentiis M, et al. Conference contribution